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SUMMARY
Due to the current epidemiological situation of pertussis, several countries have implemented
vaccination strategies that include a booster dose for adolescents. Since there is still no evidence
showing that the adolescent booster has a positive eﬀect on the most vulnerable group
represented by infants, it is diﬃcult to universalize the recommendation to include such
reinforcement. In this work we present an age-structured compartmental deterministic model that
considers the outstanding epidemiological features of the disease in order to assess the impact of
the booster dose at age 11 years (Tdap booster) to infants. To this end, we performed diﬀerent
parameterizations of the model that represent distinct possible epidemiological scenarios. The
results obtained show that the inclusion of a single Tdap dose at age 11 years signiﬁcantly reduces
the incidence of the disease within this age group, but has a very low impact on the risk group
(0–1 year). An eﬀort to improve the coverage of the ﬁrst dose would have a much greater impact
on infants. These results hold in the 18 scenarios considered, which demonstrates the robustness
of these conclusions.
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INTRODUCTION
Bordetella pertussis causes the respiratory disease
named whooping cough or pertussis that is most
severe in infants. Before massive vaccination was
introduced in the 1950s, pertussis was a major cause
of infant mortality worldwide. As a consequence of
the implementation of a pertussis immunization pro-
gramme, a marked decline in disease incidence was
observed [1, 2]. However, in the 1990s a resurgence
of pertussis was detected in diﬀerent countries and
now pertussis has become the most prevalent vaccine-
preventable disease in developed and in developing
countries [3–5]. The disease is now recognized as a
frequent infection not only for infants but also for
adolescent and adults [6]. Several explanations have
been proposed for this resurgence of the disease,
including improved surveillance, waning immunity
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and bacterial evolution [5, 7–10]. The relevance of
these factors in the resurgence of pertussis might diﬀer
between countries. Beyond the possible causes, it is
clear that the number of cases has steadily increased
which undoubtedly marks the need to revise and im-
plement strategies to improve the disease control. In
fact, in 2002 diﬀerent ministries of health, committees
and organizations like the Global Pertussis Initiative
(GPI, 2002), and Advisory Committee on Immuniz-
ation Practices (ACIP) of the USA recommended ex-
panding the existing vaccination strategies to include
a pertussis booster dose for adolescents [11, 12]. The
reported rationale for that strategy is to provide both
direct protection for the adolescents that receive the
booster and indirect beneﬁt for non-immunized peers
and the most vulnerable age groups, the infants. For
this secondary but important goal, however, there is
still no evidence showing a reduction in severe infant
disease and mortality even following the implemen-
tation of an adolescent booster dose at age 11 years
(Tdap) in diﬀerent countries. Probably a few more
years of data are needed to evaluate the real impact on
infant disease before a universal recommendation
could be considered.
Given this context, mathematical models of disease
transmission contribute to a timely analysis of the
impact of the new control strategies. In fact, an in-
creasing number of papers on pertussis modelling
have been reported [13–20]. In this work we present
an age-structured compartmental model to describe
the propagation of pertussis in Argentina and to as-
sess the impact of vaccination schedule changes on
infant disease control. The model explores scenarios
for future interventions in countries with social,
demographic and epidemiological similarities to
Argentina. Thus a brief overview of the Argentinean
epidemiological situation is given before a description
of the mathematical model.
Pertussis epidemiology in Argentina
Argentina is a South American country with a popu-
lation of 40 091 359 inhabitants, and a high life
expectancy (75.5 years) and literacy rate (97.7%),
comparable to developed countries. From the begin-
ning of pertussis vaccination in the 1970s and until
1985, the Argentinean schedule against pertussis
included three primary doses of diphtheria-tetanus-
whole cell pertussis vaccine (DTwP) at ages 2, 4 and
6 months and a booster dose of DTwP at 18 months.
In 1985, a ﬁfth DTwP dose at age 5–6 years (school
entry) was introduced. Since 2009, in accord with
international recommendations [21], an acellular per-
tussis booster dose (TdaP) was included for 11-year-
olds and healthcare workers. All pertussis vaccine
doses are distributed free of charge to the population.
The three-dose pertussis coverage is high, typically
90%. In 2010 DTwP3 average coverage for Argentina
was 92.8% [22]. However, this value is not uniform
throughout the country because there are some
regions with coverage lower than 80% [23]. The re-
ported 18-month dose coverage is in general lower
than the other doses. In 2010 the 11-year booster
coverage was 57% [22]. In Argentina, as occurred in
other countries, the introduction of mass immuniz-
ation markedly decreased pertussis hospitalizations and
deaths, reaching the lowest incidence levels in 2002
[23, 24] (Fig. 1a). Figure 1a depicts the occurrence of
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Fig. 1. (a) Pertussis incidence in Argentina during the
1969–2009 period. (b) Pertussis incidence in three
Argentinean provinces. Pertussis incidence for the whole
country is shown by dotted lines. (Source : SINAVE,
Argentinean Ministry of Health.)
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pertussis outbreaks every 3–4 years, as was also
reported for other countries [25–27]. These periodic
outbreaks were also observed in diﬀerent Argentinean
districts in the vaccine era, and since the oscillations
in incidence levels in the diﬀerent districts are out
of phase, the whole country oscillation becomes
undetectable (Fig. 1b). Since 2002 an increase in per-
tussis incidence has been observed, which was sus-
tained until the present (2012). During 2011, 8323
suspected pertussis cases were notiﬁed in the National
Surveillance System (SIVILA). From these total
cases, 6821 were registered in infants aged <1 year.
The majority of these cases corresponded to the more
populated provinces of Argentina such as Buenos
Aires, Co´rdoba and Santa Fe. From those cases, 1663
(19.98%) were laboratory-conﬁrmed pertussis cases.
In 2010, 4981 cases were registered and 828 (16.62%)
were laboratory conﬁrmed. Again most of the cases
were conﬁrmed in patients aged <1 year (4217 from
4981). The large proportion of cases recorded in
infants was not unexpected, since pertussis is most
severe in this age group. The number of pertussis
deaths during the analysed period of 2011 was around
70 (this value was extracted from national and local
reports), recorded mostly in infants aged <1 year.
As expected, young unvaccinated infants were more
likely to have a severe disease, to suﬀer complications,
to require hospitalization, or to die than older chil-
dren and adults.
METHODS
Model
We developed a deterministic age-structured com-
partmental model to evaluate the eﬀects of health
policies on pertussis incidence in infants, mainly in the
0–1 year age group. The age discrimination allows us
to simulate the application of vaccination doses at
speciﬁc ages, as well as to explore the eﬀect on per-
tussis transmission of diﬀerent age proﬁles for the
force of infection (FOI). The model described here
is based on Hethcote’s model designed in regard to
pertussis in USA [15]. Here the population is stratiﬁed
in nine epidemiological classes. Considering the
severity of pertussis infection and consequently their
infectivity, infected individuals were grouped into
three classes: I1 for severe infection, I2 for mild
infection, and I3 for weak infection. Individuals be-
longing to I1, I2, and I3 have decreasing infectivity.
Populations that are susceptible to acquiring the
infection are included in classes S, PAI
1 , PAI
2 , PAI
3 , but
while individuals in S class (fully susceptible) have
no immunity to the infection, PAI classes include
individuals with partial acquired immunity via vacci-
nation or natural infection. Classes R (recovered) and
CAI (complete acquired immunity) include individuals
fully protected against the disease.
The dynamics of pertussis propagation is simulated
by transferring individuals in diﬀerent classes at
corresponding speciﬁc transfer rates (Fig. 2). In this
model, individuals are in the susceptible class when
born, and remain there unless : (a) they become in-
fectious through contact with an infected individual
and enter the full symptomatic infective class (I1), or
(b) they acquire the lowest level of immunity through
a vaccine dose and enter the PAI
1 class. When receiving
successive vaccination doses (indicated in Fig. 2 by
dotted lines), individuals go through classes of in-
creasing immunity and eventually reach the CAI class.
Individuals in classes PAI
1 and PAI
2 may become infec-
tious but they develop a less symptomatic illness
entering class I2 (mild infection) or I3 (weak infection),
respectively. We assume that infection fades in a time
that is exponentially distributed around an average
value 1/c. After this time, individuals in infective
classes I1, I2 or I3 recover and enter class R. Indi-
viduals in PAI
3 class acquire an infection but it is so
weak that they do not become infective and so directly
enter R class. The main eﬀect of infection on PAI
3 in-
dividuals is to boost their own immunity, contributing
to herd immunity.
In this model we assume that immunity does not
last lifelong. We consider that pertussis immunity is
lost gradually. This eﬀect was simulated by transfer-
ring individuals from the classes with complete
S
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Fig. 2. Schematic representation of the epidemiological
model.
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immunity (R and CAI) to classes with decreasing
degrees of immunity (PAI
3 pPAI2 pPAI1 ). Individuals in
classes R or CAI have complete immunity against
infection for a typical time 1/s or 1/t, respectively,
in order to account for the diﬀerence of duration of
complete immunity if it has been acquired via infec-
tion or vaccination. We assume that further loss of
immunity occurs at the same rate tk, independently of
the way it has been acquired. This is a simpliﬁcation
introduced in our model with respect to the one used
by Hethcote [15]. We argue that with a careful choice
of parameters s, t and tk we may account for the
main eﬀects that introduce the diﬀerence between
natural and artiﬁcially acquired loss of immunity.
Like Hethcote we consider the possibility that after a
very long time individuals eventually become fully
susceptible. In the model this fact was included by
transferring individuals from PAI
1 to S at a rate s0.
The nine epidemiological classes described above are
divided into age groups. Thus, for fully susceptible
individuals, for example, we deﬁne Si(t) as the fraction
of individuals in class S, at time t, with age in the
interval (ai, ai+1). The FOI li is the rate at which
susceptible or partially immune individuals of age
group i acquire infection. This is the only rate in our
model that is not constant through time and depends
on the fractions of infected individuals (which are
dynamical variables of the model) through the ex-
pression:
li=
X
j
bij Ij
*; Ij
*=I1j+r1I2j+r2I3j (1)
where bij is the contact parameter matrix and Ij
* is the
eﬀective fraction of individuals of age j in the popu-
lation that is infective. Factors r1 and r2 are taken as
smaller than 1 to consider that infected individuals in
classes I2 and I3 are less infective than the ones in class
I1 as they have a milder cough. The dynamics of the
model is described by a set of coupled ordinary dif-
ferential equations discussed in the Appendix where a
detailed description of the model is included. By
solving these equations, the population of the diﬀer-
ent classes discriminated by age group as a function of
time can be obtained.
Model parameters
We deﬁne a set of ages: ai=0, 2, 4, 6, 12, 18 months,
yearly from 2 to 15 years ; every 5 years from 15 to
55 years, and every 10 years from 55 to 75 years,
which determines the nA=30 age groups: (ai, ai+1).
For infants aged <18 months the ages were chosen
taking into account the local vaccination schedule. In
this work the size of population is considered constant
in time (see Appendix). Concerning mortality rates,
mi, in this work we assume that type I mortality
(everybody dies at an age equal to life expectancy, see
Appendix for details) is an acceptable approximation
for Argentina (Supplementary Fig. S1, available
online). Although it is well known that pertussis
vaccination or infection does not provide lifelong
immunity, the precise duration of protection is not
known [9, 15, 18]. Because of that, three immunity
parameterizations were considered here: SDI, MDI
and LDI for short, medium or long duration of im-
munity, respectively, based on data from Wendelboe
et al. [9]. It is assumed that the duration of natural
immunity (tN) is the time elapsed since an individual
has recovered from infection (enters class R) until
reaching class PAI
1 where the individual may acquire a
mild infection. The duration of immunity acquired
through vaccination (tV) is the time elapsed since an
individual has been completely immunized (enters
class CAI) until reaching class PAI
1 . Table 1 lists the
values used for these parameters in the three im-
munity conditions considered. As in Hethcote’s work,
Table 1. Parameter values for the diﬀerent pertussis immunity durations
considered in this study
Duration of pertussis immunity tN tV 1/s 1/t 1/tk 1/s0
Short duration immunity (SDI) 8 4 5 1 1.5 100
Medium duration immunity (MDI) 15 6 11 2 2 100
Long duration immunity (LDI) 20 10 14 4 3 100
tN and tV are the duration of immunity acquired naturally (through infection) or
artiﬁcially (through vaccination), respectively. The rates s, t and tk are chosen to
obtain tN=1/s+2/tk, tV=1/t+2/tk. The rate at which immunized individuals be-
come completely susceptible is controlled by the slow rate, s0. All the values in the
table are in years.
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the eﬃcacy of a pertussis vaccine dose (VE) was con-
sidered equal to 0.9 [15]. Taking into account that
vaccine coverage in Argentina depends on the region
[23], we considered both high vaccination coverage of
95% for the three-dose pertussis (C95) and low vacci-
nation coverage of 80% for the three-dose pertussis
(C80). In both cases, the 18-month dose coverage
is lower than the other doses and was considered
85% and 70%, respectively, reaching the three-dose
coverage for the 6-year boost (Table 2). The trans-
mission of infection takes place through contact
between infected and susceptible (or partially im-
munized) individuals. Quantitatively, this process
is controlled by expression (1) for the FOI li.
Individuals with diﬀerent grades of infection contrib-
ute diﬀerently to li. This contribution was taken into
account with the parameters r1 and r2. In particular
the values used were those proposed by Hethcote:
r1=0.5, r2=0.25 [15]. The recovery rate is set as
c=1/(21 days) independently of the degree of infec-
tion. In order to determine bij contact parameters, two
diﬀerent procedures were followed, which led us to
consider three diﬀerent sets of contact parameters.
Procedure 1: Determination of contact parameters,
bij, from the FOI and WAIFW (who acquires
infection from whom) matrices
In the standard procedure described by Anderson &
May [25], bij is supposed to be symmetric among the
age groups and some structure for matrix b is as-
sumed in such a way that it has only few nB indepen-
dent values. This structure is usually referred to as
WAIFW matrix. If nB values of li are known from
epidemiological data, the given epidemiological
model may be solved, the Ij
* at the stationary state
of the system may be obtained, and equation (1) is
inverted in order to obtain the nB values that deﬁne
bij. The details of this procedure and the minor
modiﬁcations introduced by us in the present work
are discussed in the Supplementary online material.
A common practice in this parameterization pro-
cedure has been to take li values from the pre-vaccine
era and then use the bij parameters obtained in the
vaccine era assuming that the contact structure of the
population has not changed signiﬁcantly [15, 28].
There are, however, other models that parameterize
bij from the knowledge of FOI in the vaccine era
[16, 29]. A marked eﬀort is currently made to obtain li
values from empirical data when the immunological
situation is much more complicated than in the pre-
vaccine era [30]. In Argentina, there are no suﬃciently
accurate age-stratiﬁed data to estimate li values in the
pre-vaccine or vaccine eras. Therefore, some standard
l age proﬁles of the pre-vaccine (case A) and vaccine
(case B) eras are considered and discussed below.
FOI from the pre-vaccine era (case A)
The FOI in the pre-vaccine era could in principle be
taken from any country because the pertussis epi-
demiological situation, before massive vaccination
was implemented, was supposed to be similar in dif-
ferent countries. On the contrary, vaccination in-
troduces several new variables such as coverage of
vaccine formulations, time since application and age
cohorts that have been vaccinated, which should be
carefully considered when extrapolating parameters
from one place to another. The values used here
(shown in Fig. 3a) were based on those reported by
Hethcote [15] with a slight modiﬁcation in order to ﬁt
them in the age groups of our model. The relevant
feature of this FOI proﬁle is the peak for the 5–10
years age group. The average age at ﬁrst infection,
A1st, estimated by our model (see Appendix) is be-
tween 4.4 and 5 years as expected for pertussis [25].
It is important to note that as the determination of
bij involves the solution of the epidemiological model,
we obtain three sets of contact parameters (CP) one
for each duration of immunity considered (SDI,
MDI, LDI).
FOI based on studies in the vaccine era (case B)
In this case we follow a similar procedure as in case A
but instead of taking the FOIs of the pre-vaccine era,
we propose another procedure (see details in the
Supplementary material). This procedure was devel-
oped in order that the FOI obtained with our model
for the vaccine era shows some features recently
observed in serological and demographic studies in
several European countries [30]. These characteristics
are : a peak of pertussis incidence for teenagers,
Table 2. Pertussis vaccination coverage for C95 and C80
Age of dose application
2 mo. 4 mo. 6 mo. 18 mo. 6 yr
C95 0.95 0.95 0.95 0.85 0.95
C80 0.80 0.80 0.80 0.70 0.80
The values of coverage included in the table are prior to the
introduction of Tdap booster (at 11 years).
722 G. Fabricius and others
https://doi.org/10.1017/S0950268812001380
Downloaded from https:/www.cambridge.org/core. Open University Library, on 30 Jan 2017 at 11:07:53, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
the presence of a second broad peak at around age
45 years, and the fact that both peaks mostly share the
same height (with the exception of Italy). The FOI
both in the pre-vaccine and vaccine eras are shown in
Figure 3b. The higher values of the FOI assigned to
adults in comparison to case A, leads to higher values
for the bij parameters that describe contacts among
adults aged>35 years.
Procedure 2: Determination of bij from social contact
patterns
bi,j parameters could also be determined from direct
estimation of social contacts among diﬀerent age
groups. If a measurement of the rate cij of the social
contacts per day of an individual in age group i with
individuals of age group j were available, bij could
be approximated assuming that the probability of a
contact being infective is the same for all age groups
(see Supplementary material). An extensive study of
social contacts in eight diﬀerent European countries
relevant for airborne or close-contact infectious
diseases has been performed by Mossong and co-
workers [31]. These authors found that the eight sets
of cij obtained in the analysed countries, present
similar qualitative features. We have used the stat-
istical weighted average of the cij reported in Mossong
et al. [31] to construct another possible contact pat-
tern parameterization, even though the structure of
social contacts in our country may present its intrinsic
complexity. In Figure 3c we show the FOI predicted
from this procedure for the MDI case in the pre-
vaccine era.
A detailed description of the assumptions and
methodology used to determine bij for procedures 1
and 2, and the resulting values are presented in the
Supplementary material.
Epidemiological scenarios
In summary, for the parameterization of the model we
consider diﬀerent possible values for the three sets of
parameters that deﬁne duration of immunity, contact
patterns among people of diﬀerent age groups and
vaccine coverage. In Table 3 the notation used for
these parameters is included. From these parameters
18 scenarios in the vaccine era were deﬁned: SDI-
CP1A-C95, MDI-CP1A-C95, LDI-CP1A-C95, SDI-CP1B-
C80, … . It is important to note that each scenario
is not the combination of independent parameters.
While in the case of SDI, MDI, LDI, C95 and C80 each
deﬁnes a set of parameter values, each CP refers to the
procedure used to determine bij, but in order to obtain
bij it is also necessary to give values to parameters that
deﬁne the duration of immunity. For example, for
CP1A we have three sets of bij, one for MDI, another
for SDI and another for LDI.
RESULTS
Our study evaluates the impact of an adolescent
booster dose (Tdap) on the most vulnerable 0–1 year
age group using an age compartmental deterministic
model. For all the calculations here presented we
considered that coverage for Tdap dose is 85% even
though the current coverage is 57%. This assumption
was performed expecting that in the following years
Tdap coverage will increase as was the case with the
other vaccines introduced in the national immuniz-
ation schedule.
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Fig. 3. Force of infection (FOI) for medium duration of
immunity in the pre-vaccine era (–––) and vaccine era (- - -)
with C95 coverage. Data in panels (a) and (b) have been used
to parameterize the model in procedure 1, cases A and B,
respectively. Panel (c) shows the FOI obtained with the
model when procedure 2 is used to parameterize bij.
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Speciﬁc age incidences
The major focus of our attention was on pertussis
incidence of fully (Inc1) and mild (Inc2) symptomatic
pertussis cases, which are the most risky classes
(infected and infective). These incidences may be
computed for each age group as follows:
Inc1i=liSi, Inc2i=liP1AIi
Inc1, in an age interval D, means the sum of Inc1i for
all age groups contained in D. Speciﬁc age incidence
(SAI) in interval D is deﬁned as (Inc1+Inc2)/D. Inc1
and Inc2 depend on time through the dynamical
variables li Si, PAIi
1 . However, all the results presented
here and in the following section refer to the
stationary values of incidences. We ﬁrst focus on the
CP1A-MDI scenario since contacts among individuals
are based on standard FOIs that have been widely
used by diﬀerent authors [15, 25]. Regarding loss of
immunity, MDI parameters correspond to the mean
reported values and are similar to the ones used by
Hethcote [15, 32]. In this scenario SAIs for diﬀerent
age groups were calculated both in the pre-vaccine era
and in the vaccine era with or without the extra dose
at age 11 years. The results obtained are shown in
Figure 4. The ﬁgure shows that in the pre-vaccine era,
Table 3. Pertussis epidemiological scenario parameters
Epidemiological features considered
to deﬁne scenarios
Set of
parameters
Values of
parameters :
Duration of immunity (DI)
SDI: Short s, t, tk, s0 Table 1
MDI: Medium
LDI: Long
Contact parameters (CP)
CP1A: from procedure 1 (case A) bij Tables S1, S2*
CP1B: from procedure 1 (case B) Tables S1, S2*
CP2 : from procedure 2 Table S3*
Vaccine coverage
C95 : 95% for ﬁrst three doses pi Table 2
C80 : 80% for ﬁrst three doses
* See Supplementary tables in the online Supplementary material.
Each combination of DI-CP vaccine coverage deﬁnes a speciﬁc ‘scenario’.
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Fig. 4. Eﬀect of C95 vaccination schedule on the age-speciﬁc pertussis incidence for the CP1A-MDI scenario. Results
considering an extra 11-year booster dose are also presented.
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pertussis was an infection which mainly aﬀected
children. After the introduction of pertussis vaccine
the incidence of disease in children declined markedly,
particularly in the 0–5 years age group, where
Inc1+Inc2 decreased by a factor of 5. Although lower
than in the pre-vaccine era, in the vaccine era a peak
of pertussis incidence is detected in children in the
5–10 years age group. Moreover, in this era the SAI
of adolescents aged 10–15 years is higher than that of
the pre-vaccine era, probably as a consequence of
the shorter duration of the immunity conferred by
vaccination than that acquired by natural infection
(Table 1). These changes in the calculated SAI caused
by vaccination are in agreement with those previously
reported in other studies that employed similar par-
ameters to analyse pertussis in USA [15] and in Rio de
Janeiro (Brazil) [17]. Figure 4 shows that the addition
of the Tdap 11-year booster decreases the incidence of
this age group but it has no signiﬁcant eﬀect on in-
fants. We have even found that regardless the scenario
considered the eﬀect of adding an 11-year booster is
still very small for children (Supplementary Fig. S2,
online). Moreover, even when the coverage of the ﬁrst
ﬁve doses was low (C80) or the incidence in adolescents
was particularly high, the inclusion of an extra
Tdap booster would not improve the epidemiological
situation of children (Supplementary Fig. S2).
Incidences for infants aged<1 year
We then evaluated the eﬀect of adolescent booster on
pertussis incidence in infants aged <1 year for all
scenarios analysed as shown in Table 4. We observed
that beyond the diﬀerences in Inc1 and Inc2 in the
scenarios considered, the eﬀect of the addition of
Tdap booster either on Inc1, Inc2 or Inc1+Inc2 sum, is
<5% in all cases. The eﬀect of including the Tdap
booster was also compared with the eﬀect of improv-
ing the coverage of the ﬁrst three doses. In Figure 5,
the 0–1 year incidence (Inc1+Inc2) values for the nine
scenarios, for C95 and C80 coverage, are shown.
It is clear that beyond the immunity duration or the
contact scenario considered, improving vaccination
coverage produces a signiﬁcant decrease in 0–1 year
incidence (between 22% and 32%) in comparison
with the incorporation of the booster at age 11 years
(below 5%). These data indicate that increasing the
coverage of the ﬁrst dose (at 2, 4 and 6 months) would
result in a substantial improvement in the control of
this disease.
Dynamical behaviour
The deterministic compartmental model presented
here predicts that the system will reach a stationary
equilibrium state that represents the endemic phase
of the disease. Any disturbance of this equilibrium
generates pronounced oscillations in the dynamical
variables of the model that are smoothly damped over
time. In particular, the introduction of the Tdap
booster produces an oscillatory behaviour of inci-
dence that is shown in Figure 6. The ﬁgure shows the
dynamical evolution of Inc1(t)+Inc2(t) for 10 years
for the 11–13 and 0–1 years age groups. Two years
after introduction of the booster, when incidences at-
tained their minimum, the drop of incidence observed
in the ﬁgure for the 11–13 years group is about 47%,
while for the 0–1 year group it is about 13%.
Table 4. Eﬀect of Tdap booster dosing on 0–1 year incidence
Scenario
Without Tdap
11-year booster
With Tdap
11-year booster
Diﬀerence in incidence with and
without Tdap 11-year booster (%)
Inc1 Inc2 Inc1 Inc2 Inc1 Inc1+Inc2
CP1A-SDI 6.6 16.7 6.4 16.3 2.8 2.6
CP1A-MDI 7.3 15.0 7.2 14.7 2.1 2.2
CP1A-LDI 7.3 12.4 7.0 12.0 3.3 3.7
CP1B-SDI 7.4 21.5 7.3 21.3 2.2 1.5
CP1B-MDI 8.8 19.3 8.7 19.1 1.0 1.1
CP1B-LDI 9.0 16.5 8.9 16.3 1.2 1.4
CP2-SDI 13.6 19.6 13.2 19.2 2.4 2.4
CP2-MDI 10.2 13.8 9.9 13.4 3.1 3.0
CP2-LDI 7.8 9.9 7.5 9.4 4.0 4.1
CP, Contact parameter ; SDI, short duration immunity ; MDI, medium duration immunity ; LDI, long duration immunity.
Incidences are given in cases/year per 100 000 population.
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Moreover, the incidence for the 11–13 years group
oscillates around a new equilibrium value that is
43.5% lower than before the introduction of the
booster. On the other side, in the 0–1 year group in-
cidence oscillates around a value very similar to the
one it had before introduction of the booster (only
2% lower). The oscillatory behaviour of pertussis
incidence has been predicted by both stochastic
and deterministic epidemic models [14, 18, 33]. The
periods of outbreaks predicted by our model in the
three MDI scenarios are shown in Table 5 and lie
within the expected values for pertussis [25–27]. In
particular, the observed period of 4 years for pertussis
in Argentina (Fig. 1b) is well estimated by any of the
scenarios considered. It should be noted that a precise
prediction of the value of inter-epidemic period has
remained very elusive as it depends on details in the
model description, such as age dependence of the FOI
[14], a stochastic treatment of the ﬂuctuations in
the network of contacts where the disease spreads
[34] and the consideration of deterministic recovery
[34, 35]. Therefore, the results shown in Table 5
should not be interpreted as indicating that a certain
scenario is better than another one because of a better
prediction of the period of oscillations.
Sensitivity of the previous results to diﬀerent factors
that may inﬂuence disease transmission
Variation of VE
Adequate estimates of VE per dose are diﬃcult,
particularly in our country, because Argentina uses
imported vaccines from diﬀerent companies which
varies from year to year. Because of that in this work
we use the value of 0.9 estimated by Hethcote from
USA epidemiological data [15]. However, as VE
enters our model as a multiplying factor of vaccine
coverage pk, we may evaluate the eﬀect of a lower VE
when assessing the results for a lower coverage. Our
results show that an adolescent booster has the same
low eﬀect in 0–1 year incidence when the coverage is
reduced from 95% to 80%. Therefore, diﬀerent VE
values are not expected to modify the conclusions of
our work.
Predicted eﬀect of maternal immunity transmission
(MIT) in newborn protection
Using our model we also analysed the eﬀect of
the transfer of immunity from mothers to infants in
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Fig. 5. Eﬀect of adolescent booster dosing on 0–1 year in-
cidence (Inc1+Inc2) in all scenarios for C95 and C80 cover-
age. Three durations of immunity were considered: short
(upper panel), medium (middle panel) and long (lower
panel).
Table 5. Inter-epidemic periods obtained for the MDI
scenarios in the pre-vaccine and vaccine eras with C95
or C80 coverage
Scenario
Pre-vaccine
era
Vaccine era
C95 C80
CP1A-MDI 2.7 4.2 4.0
CP1B-MDI 3.0 3.6 3.6
CP2-MDI 3.6 5.0 5.0
CP, Contact parameter ; MDI, medium duration immunity.
Values given are in years.
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pertussis transmissibility. To this end, an extra class
X0 was added to our model. This class includes
individuals who acquired maternal antibodies and
because of that, they would present mild symptoma-
tology (I2) if they become infected. The modiﬁcations
introduced to the model equations when MIT is con-
sidered are described in the Appendix. Performing
calculations for the CP1A-MDI scenario, and as-
suming that maternal antibodies will last 2.5 years, we
observed that MIT reduces the incidence Inc1 in the
0–1 year group by 10%. If we consider adolescent
booster dosing, the eﬀect of boosting in reducing
0–1 year incidence appears to be the same for this
modiﬁed model that includes newborn protection as
for the original model (typically 2%). Based on these
results and using the modiﬁed model that includes the
X0 class, a rough approximation of the eﬀect that
mother booster dosing would have on infant inci-
dence was estimated. If we consider that 50% of
mothers are immunized, the calculated reduction for
Inc1 would lie around 33%. It should be noted that
although this reduction in Inc1 is associated directly
with an equal increase in Inc2, it is a desirable eﬀect
since the severe form of the disease in children is
reduced. In fact, the decrease of the full infection in
the most vulnerable population with highest risk of
hospitalization and death, is one of the goals pursued
by the health system. The results presented in this
section agree with the recommendations recently
made by the ACIP of the USA CDC related to the use
of Tdap vaccine in pregnant women [12].
Analysis of the eﬀect of immune memory on pertussis
transmission
There is evidence that immune memory cells exposed
again to an antigen through infection or a complete
vaccination scheme exhibit a more eﬃcient response
than naive cells. Therefore it is reasonable to suppose
that a pertussis booster vaccination in individuals
who have had a previous pertussis infection or at least
three vaccine doses would confer the highest degree
of immunity. We considered this eﬀect in our model
sending those individuals that exhibit a more eﬃcient
response directly to class CAI when a booster is
applied independently of their presence in class PAI
1 ,
PAI
2 or PAI
3 . These modiﬁcations were introduced
in our model (see Appendix for details) and the
computations of incidence for CP1A-MDI scenarios
repeated. The results (Table 6) point out that, even
though the 11-year dose is predicted to be more
eﬀective by this modiﬁed model, it still shows a low
impact on young infant incidence (below 5%). In any
case, the introduction of the adolescent booster
in the vaccination schedule displays a minor eﬀect
in reducing incidence in the 0–1 year group. This
memory eﬀect was also considered by other authors in
SIR-based models including three types of partial
immunity classes : removed, vaccinated and waning
immunity classes [32].
Another way in which immune memory may aﬀect
pertussis transmission has recently been analysed by
Lavine et al. [19]. These authors considered in their
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Fig. 6. Dynamical behaviour of incidence (Inc1+Inc2) for the CP1A-MDI scenario with C95 vaccination coverage after
introduction of the 11-year booster. Time is measured from the booster introduction.
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transmission model that individuals could receive
frequent natural boosters when exposed to a small
number of bacteria. This possibility was also con-
sidered in our model taking a rate kl instead of l for
individuals that go from PAI
3 to R class (see Fig. 2).
When considering the CP2-MDI scenario taking k=2,
our results show that in the vaccine era (C95) the sys-
tem presents pronounced epidemic outbreaks similar
to those obtained by Lavine et al. for high coverage
[19] with no stationary state. Even when the dynami-
cal description of the system predicted by our model
when considering this boosting eﬀect is very diﬀerent,
the values of mean incidence for infants are very
similar. In particular, the eﬀect of adding the 11-year
booster in infants implies a 3% reduction of 0–1 year
incidence, as we have previously shown for our model
(see Table 4). A detailed study of the consequences
of introducing this eﬀect in our model of pertussis
transmission is beyond the scope of the present work
and will be addressed elsewhere.
DISCUSSION
With the recommended application of the Tdap
booster in adolescents, not only a reduction in ado-
lescent pertussis incidence is expected but also an in-
direct beneﬁt for infants could be achieved. This last
objective seems to be feasible since the immunization
of adolescents would remove at least in part the
source of infection for infants. However, since cur-
rently there is no evidence to support this rationale, it
is diﬃcult to produce a universal recommendation to
extend vaccination programmes to adolescents. Given
this situation and to promptly assess the impact of the
adolescent booster in infants, we designed a determi-
nistic age-structured compartmental model based on
two assumptions regarding pertussis immunity and
transmission that are largely agreed upon: immunity
has an important eﬀect on the severity of disease,
and immunity wanes over time. In this sense, the
population in our model is stratiﬁed in nine classes
(Fig. 2). With this model diﬀerent possible epi-
demiological scenarios (n=18) were explored since
there are uncertainties in some parameters such as
the rate of infectious contacts between people of dif-
ferent ages and also the exact duration of protective
immunity.
In the 18 scenarios considered we could reproduce
not only the drop in the incidence of children caused
by the massive use of pertussis vaccine but also the
fact that the SAI of the 10–15 years group was higher
in the vaccine era than in the pre-vaccine era. These
features reproduced here were evidenced by epi-
demiological studies in several countries [36] and
diﬀerent models [15, 17]. It is important to note,
however, that the magnitudes of the vaccine eﬀects
calculated here do not correlate with the data re-
ported, probably due to underreporting of the disease.
The general consensus is that the reported cases
are probably much lower than the true incidence of
pertussis. Because of this underreporting, the total
pertussis incidence in the vaccine era predicted by the
model, are much higher than those reported by
national surveillance systems. The magnitude of the
observed incidence reduction in Argentina due to
vaccination (Fig. 1) is predicted by the model only for
the incidence of fully symptomatic cases, Inc1. This is
the case, for example, for the calculated value of Inc1
in the 0–5 years age group which is reduced by a
factor of 75 from the pre-vaccine to the vaccine
endemic equilibrium in the CP1A-MDI-C95 scenario.
This agreement between the reported data and the
calculated values of children (Inc1) was also found in
simulations of pertussis in USA [15] and supports
Table 6. Comparative analysis of the eﬀect of Tdap booster dosing on the 0–1 year incidence simulated using
unmodiﬁed and modiﬁed models
Without boost With boost (at 11 years) Percent change
Inc1 Inc2 Inc1 Inc2 Inc1 Inc1+Inc2
C95 Unmodiﬁed model 7.3 15 7.2 14.7 2.1 2.2
Modiﬁed model 6.9 14.1 6.6 13.4 5 5.4
C80 Unmodiﬁed model 10.2 22.1 10 21.7 1.5 1.6
Modiﬁed model 9.9 21.4 9.6 20.7 3 3.2
Calculations were performed for the CP1A-MDI scenario with C95 or C80 coverage.
In the modiﬁed model immunity memory eﬀects are taken into account by subdividing classes PAI
1 and PAI
2 (see Appendix for
more details).
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the idea that the health system mainly detects child
fully-symptomatic cases. The above-mentioned under-
reporting would be more pronounced in adolescents
or adults where normal prolonged cough may be the
only clinical feature. This underreporting makes it
diﬃcult to use notiﬁed data to decide which of the
18 scenarios is the best ﬁt to reality. Following
this rationale, diﬀerent scenarios were considered to
perform our analysis.
To evaluate the eﬀect of the incorporation of the
11-year Tdap in the National Vaccination Schedule,
we performed calculations for all considered scen-
arios. The results obtained showed that the 11-year
Tdap booster decreases the incidence of the disease
in this age group. This result is in agreement with the
reported [37, 38] and predicted [29] data. When the
eﬀect of the introduction of an adolescent booster
in infants was analysed, our results showed that the
Tdap booster also reduces incidence in infants but to
a very low extent. The calculated decrease does not
exceed 5% for any of the scenarios considered. Since
none of the variations included in the epidemiological
scenarios leads to a reduction higher than 5%, the
prediction of the model proves to be robust. This re-
sult is in agreement with those reported by other
authors using diﬀerent models and parameterizations
to obtain similar results [19, 29]. Moreover, in some
stochastic models in which it is considered that
pertussis immunity is not lost, the reinforcement at
11 years does not impact in reducing the incidence in
infants [20]. All these studies suggest that widespread
adolescent vaccinations may not bring about the re-
duction in pertussis cases some had hoped. This could
be explained at least in part by the relatively low
weight that adolescents have as a source of infection
in infants [39–41]. In fact, a recent work shows
that adolescents exhibit diﬀerent seasonal pertussis
peaks compared to infants, suggesting that children
and adults (possibly parents), not adolescents, are the
main sources of infant infection [42]. The outcome
of immunization of the relatively low fraction of
adolescents that is a source of infant infection could
be even lower because of Tdap eﬃcacy, coverage
and duration of immunity which do not ensure that
the whole adolescent population is protected by the
booster. This rationale supports the results predicted
by our model.
Importantly, using our model we were able to
demonstrate that, in countries such as Argentina
where some regions have relatively low vaccine
coverage, improving coverage of the ﬁrst dose has
a more beneﬁcial impact in reducing incidence in
infants than the vaccination of adolescents. In fact, a
key outcome of our study is that increasing coverage
of the ﬁrst dose (at 2, 4 and 6 months) from 80% to
95%, would result in a substantial reduction on infant
incidence in all scenarios considered (between 22%
and 32%). However, in countries with a high cover-
age, a reduction of 5% in incidence could be assessed
as positive. In this sense, Rosenbaum, using an age-
structured compartmental deterministic model found
that among several proposed vaccination strategies
for The Netherlands (where coverage of ﬁrst dose is
96%) the optimum one is the addition of 12-year
booster dose which produces a 5.5% reduction in
infant infection [29]. Beyond the high vaccination
coverage that could be achieved in a country, there
are other strategies that may be better than vacci-
nation in adolescents. In this sense modiﬁcations
performed in our model evidence that vaccination
of mothers during pregnancy would be a more eﬀec-
tive strategy to protect infants than vaccination
of adolescents. These results are consistent with
recent widespread recommendations on vaccination
of mothers after 20 weeks of gestation [12].
In summary, in this work we evaluate the
Tdap booster impact on infant incidence considering
some features relevant to pertussis transmission.
We worked in the framework of deterministic com-
partmental age-structured models and have studied
several epidemiological scenarios covering a wide
range and combination of parameters. The impact of
the Tdap booster on infants was also assessed by
modifying our model in order to include the eﬀect of
transmission of mother immunity and the memory
immune response of individuals. The results obtained
showed that our predictions concerning the eﬀect of
Tdap booster in infants are robust. It is important to
mention, however, that there are some other aspects
of pertussis transmission that we have not explored as
they introduce further complexities or they exceed the
framework of our model and will be considered in
depth in future work. This is the case of stochastic
eﬀects, heterogeneity of contacts because of social
membership or regionality, changes in circulating
bacteria, and several correlations that could be
introduced properly in an agent-based model.
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APPENDIX
Mathematical description of the model
In our model individuals are assigned to one of the nine epidemiological classes S, PAI
1 , PAI
2 , PAI
3 , CAI, I1, I2, I3,
and R, based on their immunity to pertussis and infection status. We also deﬁne an age set : a0, a1, a2, …, and
divide the population into age groups, where the age of the individuals in age group ‘ i ’ is in the interval : (ai, ai+1).
The epidemiological state of the population is speciﬁed by the fraction of individuals (with respect to the total
population) in each one of the epidemiological classes : Si, PAIi
1 , PAIi
2 , PAIi
3 , CAIi, I1i, I2i, I3i, Ri, for each one of the
nA age groups, i=0, …, nA – 1. The dynamical evolution of these variables monitors the propagation of the
disease and is described by the following set of ordinary ﬁrst-order coupled diﬀerential equations:
dSi
dt
=xliSi+s0P1AIixmiSi+cix1(1xvacci)Six1xciSi+di0B
dP1AIi
dt
=xliP1AIixs0P
1
AIi+t
0P2AIixmiP
1
AIi+cix1(1xvacci)P
1
AIix1xciP
1
AIi+cix1vacciSix1
dP2AIi
dt
=xliP2AIixt
0P2AIi+t
0P3AIixmiP
2
AIi+cix1(1xvacci)P
2
AIix1xciP
2
AIi+cix1vacciP
1
AIix1
dP3AIi
dt
=xliP3AIixt
0P3AIi+tCAIixmiP
3
AIi+sR+cix1(1xvacci)P
3
AIix1xciP
3
AIi+cix1vacciP
2
AIix1
dCAIi
dt
=xtCAIixmiCAIi+cix1CAIix1xciCAIi+cix1vacciP
3
AIix1
dI1i
dt
=liSixcI1ixmiI1i+cix1I1ix1xciI1i
dI2i
dt
=liP1AIixcI2ixmiI2i+cix1I2ix1xciI2i
dI3i
dt
=liP2AIixcI3ixmiI3i+cix1I3ix1xciI3i
dRi
dt
=liP3AIi+c(I1i+I2i+I3i)xsRxmiR+cix1Rix1xciRi
9>>>>>>>>>>>>>>>>>=
>>>>>>>>>>>>>>>>>;
(A1)
In writing these equations we assume that the total population is constant in time. Even though the annual mean
growth rate in Argentina was 9.6% in the 2000–2005 period, this is a reasonable approximation considering we
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are not interested in describing the dynamics of the model during long time intervals. For a similar model
Hethcote has considered a variation of the total population with time for propagation of pertussis in USA
throughout 100 years. His results show, that even for this long time lapse, patterns of incidences and age
distributions are not considerably aﬀected by considering a constant population size [15]. The rates s, s0, t, tk
and c are constant in time and have been deﬁned in the Methods (Models) section, mi is the mortality rate for age
group i, and ci is the rate at which individuals are transferred from an age group to the next because of ageing.
We take ci=1/(ai+1 – ai) for i=0, …, nA – 2, in that way, for class I1 for example, in an interval Dt a fraction
Dt/(ai – aix1) of individuals in age group i – 1 are transferred to group i because of ageing, while a fraction
Dt/(ai+1 – ai) leaves group i to enter i+1. Note that there is no younger group than i=0 or older than nA – 1, so
we take cx1=cnAx1=0 in order to cancel the corresponding terms in the set of diﬀerential equations. Vaccination
is taken into account by transferring individuals from the S or PAI classes to the following increased immunity
class when a vaccine dose is applied. This is introduced in the model through the function vacci, the fraction of
individuals at age ai that are successfully immunized. For example, if a dose is applied at age ai, the rate ci, at
which individuals are transferred from Six1 to Si because of ageing [ﬁrst equation in (A1)], has to be multiplied by
a factor (1 – vacci) because the immunized individuals have been added to PAIi
1 in the last term of the second
equation. So, vacci is diﬀerent from 0 only when ai coincides with the age of one of the application doses, dk,
vacci=
Xnd
k=1
fkd
*
ik, fk=pk:VE , d
*
ik=
1 if ai=dk
0 if not,

(A2)
where fk is the fraction of people at age dk successfully immunized, pk is the coverage of k dose, nd is the number
of doses applied, and VE the vaccine eﬃcacy. In order that this scheme works, ages ai have to be chosen in such a
way that each dk coincides with some ai.
The last term in the ﬁrst equation of the system (A1) represents the birth rate. The symbol d is the Kroenecker
delta, so, di0 indicates that the term is present only for i=0. In principle, we assume that every individual is born
susceptible, so B is the per capita birth rate and is included in the equation for S0. In order to keep the total
population constant, B should equal the per capita mortality rate, so we take
B=
XnAx1
i=0
miNi, (A3)
where Ni is the fraction of the population in age group i.
The FOI is the rate at which a susceptible (or partially immune) individual in age group ‘ i ’ acquires infection,
and it is calculated as follows:
li=
X
j
N C (i, j) (I*j =Nj)=
X
j
bij I
*
j ; I
*
j=I1j+r1I2j+r2I3j, (A4)
where N c(i, j) is the number of infective contacts per unit of time between an individual of age group i with
individuals of age group j, and (Ij
*/Nj) represents the eﬀective probability that an individual in age group ‘ j ’ is
infective. For ‘ infective contact ’ we mean a contact such that if an individual in group j is fully infected (I1) and
an individual in group i is partially or completely susceptible, then an individual in group i will acquire infection.
The contact parameter matrix, bij=N c(i, j)/Nj, gives a measure of the contact rate between individuals of dif-
ferent age groups that is independent of age group sizes.
Once a choice of all the parameters is made, an initial epidemiological state for the population is chosen, and
the system of equations (A1) is solved numerically by Euler integration taking a small enough time interval, Dt,
until the stationary state is reached.
Modiﬁcations introduced to the model in order to account for the eﬀect of MIT in newborn protection
We add to our model an extra class X0. This class includes individuals who acquired maternal antibodies and
because of that if they became infected, they would present mild symptomatology (I2). Since it is known that
the duration of maternal antibodies does not exceed 2 months, the fraction of individuals in X0 that are not
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vaccinated with the corresponding 2-month dose would go directly to the susceptible class. In contrast, the X0
fraction that gets vaccinated would move to class PAI
1 . At this point it is important to note that the new class X0
included in the model is formed only by the 0–2 months age group. Assuming that mother’s antibodies will last
tA since they entered class R and that the typical time that the individuals spend in class R is 1/s, the fraction of
mothers that are able to transmit antibodies to their babies is fA=s.tARM. Where RM is the fraction of mothers
in class R (fraction of individuals aged between 20 and 35 years that are in class R). With these assumptions,
fA represents the fraction of newborns that go to class X0, and 1 – fA represents the fraction that goes to class S.
The time evolution of the fraction of individuals in class X0 is given by the equation:
dX0
dt
=xl0X0xm0X0xc0X0+BfA:
All other equations of the model remain the same as in (A1), with the exception of those given below:
dS0
dt
 
MIT
=
dS0
dt
 
A1
xBfA,
dI20
dt
 
MIT
=
dI20
dt
 
A1
+l0X0,
dS1
dt
 
MIT
=
dS1
dt
 
A1
+c0(1xvacc1)X0,
dP1AI1
dt
 
MIT
=
dP1AI1
dt
 
A1
+c0vacc1X0:
where the subindex MIT denotes the magnitude considering maternal immunity transmission and the subindex
A1 denotes the expression given in the formula (A1). Taking tM=2.5 years we obtain for the CP1A-MDI
scenario: fA=0.12.
Modiﬁcations introduced to the model in order to account for the eﬀect of immune memory on pertussis
transmission
In order to consider the more eﬃcient response exhibited by individuals that have been previously immunized
(via infection or three vaccine doses), the classes PAI
1 and PAI
2 were subdivided into two subclasses, one containing
individuals that come from S class (with naive cells) and other containing those that come from PAI
3 class (with
immune memory cells). The fraction of individuals in classes PAI
1 and PAI
2 and age group i is written:
P1AIi=P
1(n)
AIi+P
1(m)
AIi ,
P2AIi=P
2(n)
AIi+P
2(m)
AIi ,
where we have explicitly separated the contributions from individuals with naive cells (n) and immune memory
cells (m). Both these subclasses then evolve in time in an independent way with the following diﬀerence : when
individuals in an n subclass receive a vaccine dose, they increase their immunity gradually following the
dynamics of Figure 2 (PAI
1 pPAI2 pPAI3 ), while individuals in an m subclass go directly to class CAI when vacci-
nated. The dynamics are described by the following equations:
dP
1(n)
AIi
dt
=xliP
1(n)
AIixs0P
1(n)
AIi+t
0P2(n)AIixmiP
1(n)
AIi+cix1(1xvacci)P
1(n)
AIix1xciP
1(n)
AIi+cix1vacciSix1
dP
1(m)
AIi
dt
=xliP
1(m)
AIi xs0P
1(m)
AIi +t
0P2(m)AIi xmiP
1(m)
AIi +cix1(1xvacci)P
1(m)
AIix1xciP
1(m)
AIi
dP
2(n)
AIi
dt
=xliP
2(n)
AIixt
0P2(n)AIixmiP
2(n)
AIi+cix1(1xvacci)P
2(n)
AIix1xciP
2(n)
AIi+cix1vacciP
1(n)
AIix1
dP
2(m)
AIi
dt
=xliP
2(m)
AIi xt
0P2(m)AIi +t
0P3AIixmiP
2(m)
AIi +cix1(1xvacci)P
2(m)
AIix1xciP
2(m)
AIi
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dP3AIi
dt
=xliP3AIixt
0P3AIi+tCAIixmiP
3
AIi+sR+cix1(1xvacci)P
3
AIix1xciP
3
AIi+cix1vacciP
2(n)
AIix1
dCAIi
dt
=xtCAIixmiCAIi+cix1CAIix1xciCAIi+cix1vacciP
3
AIix1+cix1vacciP
2(m)
AIix1+cix1vacciP
1(m)
AIix1
where the equations for the time derivatives of Si, I1i, I2i, I3i and Ri are the same as in (A1).
Age at ﬁrst infection
We estimate the average age at ﬁrst infection, A1st, through the expression
A1st=
X
i
AiliSi=
X
i
liSi, (A5)
where Ai=(ai+1+ai)/2 and the sums are limited to include individuals with ages lower than a given Amax in order
to avoid returning to the S class of adults. In our model, immunized adults lose their immunity and are allowed
to become susceptible at a very low rate s0, but they should not be considered in the evaluation of A1st. We
only compute A1st in the pre-vaccine era and observe that it takes a reasonable value when Amax is between ages
10 and 20 years, when most ‘ﬁrst infections’ have already occurred.
Type I mortality
In this approximation it is assumed that everybody dies exactly at an age equal to the life expectancy: L [25]. In
the present work all the mortality rates mi are 0 with the exception of that corresponding to the oldest group,
i=nA – 1, which takes the value: 1=(anAxanAx1). As the total population is constant, all theNi are also constant :
Ni=(ai+1 – ai)/L, and the birth rate is B=1/L. L=anA (the highest age considered)=75 years in this work.
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